Understanding the role of obesity in endocrine therapy for postmenopausal breast cancer: significance of the BIG 1–98 and ATAC trial data
Abstract Obesity is a known risk factor for poor breast cancer outcomes, but its impact on endocrine therapy efficacy remains unclear. While the ATAC trial suggests reduced effectiveness of aromatase inhibitors (AIs) in women with obesity, the BIG 1–98 trial found no significant differences. Clinica...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer
2025-07-01
|
| シリーズ: | Discover Oncology |
| オンライン･アクセス: | https://doi.org/10.1007/s12672-025-02857-w |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|